Indication to post-operative radiotherapy for oral cavity squamous cell carcinoma: what's new in the depth of infiltration (DOI) era?
Journal
The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125
Informations de publication
Date de publication:
01 Apr 2022
01 Apr 2022
Historique:
pubmed:
18
12
2021
medline:
24
3
2022
entrez:
17
12
2021
Statut:
ppublish
Résumé
The last edition of the American Joint Committee on Cancer (AJCC eighth) has introduced the depth of infiltration (DOI) as a new prognostic parameter in oral cavity squamous cell carcinomas (OCSCCs). The aim of this study is to analyze the impact of stage migration on the indication to post-operative radiotherapy (PORT). OCSCCs treated at two institutions between 2014 and 2019 were retrieved. As per the AJCC eighth, only pT3 primarily OCSCCs were considered; availability of the pathologic specimen was a further inclusion criterion. Risk factors considered for PORT were: pT3-pT4, nodal involvement, positive/close surgical margins, perineural and lymph vascular invasion. 149 patients staged as pT3 AJCC eighth were included. A four-fold increase in the number of patients staged as pT3 from the seventh to the eighth AJCC was found. Stage migration to pT3 was equally due to the downstaging from former pT4 (38%) and upstaging of former pT1-pT2 (35%). Considering the former pT1-pT2 53 patients, 13 (25%) had no risk factors for PORT other than DOI. Among 25 cases with former pT1-pT2 and negative lymph nodes, no additional risk factors were found in 11 (44%). 90% of patients had at least one risk factor besides DOI and would have received PORT also according to the AJCC seventh; notably, of former pT1-pT2N0, half of them have been upstaged to pT3 in the current TNM classification. The role of PORT in this cohort of patients has not been clarified yet. Other-than-DOI risk factors leading to PORT indication are highly prevalent in OCSSC patients classified as pT3 per the latest AJCC TNM staging system and should therefore be considered for a comprehensive oncological assessment.
Identifiants
pubmed: 34919446
doi: 10.1259/bjr.20210705
pmc: PMC9153723
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20210705Références
Head Neck. 2018 Jun;40(6):1287-1295
pubmed: 29522275
Head Neck. 2005 Dec;27(12):1080-91
pubmed: 16240329
J Cancer Res Ther. 2020 Apr-Jun;16(3):425-433
pubmed: 32719246
Radiother Oncol. 2012 Apr;103(1):57-62
pubmed: 22296746
Cancer. 2018 Jul 15;124(14):2948-2955
pubmed: 29757457
Ann Transl Med. 2019 Jul;7(Suppl 3):S84
pubmed: 31576293
Lancet Oncol. 2011 Feb;12(2):127-36
pubmed: 21236730
Oral Oncol. 2007 Sep;43(8):764-73
pubmed: 17174140
Head Neck. 2018 Aug;40(8):1780-1787
pubmed: 29707840
Cancer. 2009 Apr 1;115(7):1489-97
pubmed: 19197973
Oral Oncol. 2002 Jun;38(4):394-7
pubmed: 12076706
Head Neck. 2019 May;41(5):1178-1183
pubmed: 30773733
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Cancers (Basel). 2021 Sep 28;13(19):
pubmed: 34638335
JAMA Otolaryngol Head Neck Surg. 2014 Dec;140(12):1138-48
pubmed: 25075712
Int J Oral Maxillofac Surg. 2015 Feb;44(2):143-50
pubmed: 25457829
Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Dec;120(6):e227-31
pubmed: 26437576
Oral Oncol. 2018 Oct;85:82-86
pubmed: 30220324
Cancer. 2019 Sep 1;125(17):2975-2983
pubmed: 31090934
Head Neck. 2019 Jun;41(6):1935-1942
pubmed: 30801885
Am J Surg Pathol. 2005 Feb;29(2):167-78
pubmed: 15644773
Crit Rev Oncol Hematol. 2019 Nov;143:67-75
pubmed: 31499275